文献速递免疫规划卫生政策与健康促进

评估65岁及以上成年人接种COVID-19 mRNA疫苗后潜在不良事件:美国两项自身对照研究

Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
PubMed 文献 · Vaccine · 2023-06-14

在美国≥65岁Medicare受益人中开展两项自身对照病例系列研究,评估COVID-19 mRNA疫苗(BNT162b2和mRNA-1273)接种后不良事件风险。基础免疫研究纳入3,360,981人共6,388,542剂次,加强针研究纳入6,156,100人接种一剂单价加强针。结果不支持mRNA疫苗升高ITP、DIC、心肌炎/心包炎和贝尔麻痹风险,AMI、ITP、DIC、BP、Myo/Peri未见风险增加,PE证据不一致,支持美国老年人群中COVID-19 mRNA疫苗的良好安全性。

要点

  • 基础免疫后AMI、ITP、DIC、PE及加强针后AMI、PE、ITP、BP、Myo/Peri的调整IRR已估算。
  • 结果不支持COVID-19 mRNA疫苗升高ITP、DIC、Myo/Peri和BP风险。
  • AMI、ITP、DIC、BP、Myo/Peri未见风险增加,PE无一致证据。

核心结论

  • 未发现COVID-19 mRNA基础免疫或单价加强针接种后AMI、ITP、DIC、BP和Myo/Peri风险增加,PE无一致证据。
  • 结果支持美国老年人群接种COVID-19 mRNA疫苗的良好安全性特征。

研究设计与样本

  • 在美国≥65岁Medicare受益人中对COVID-19 mRNA疫苗(BNT162b2和mRNA-1273)开展两项自身对照病例系列研究。
  • 基础免疫研究纳入3,360,981人,共接种6,388,542剂次基础免疫剂量。
  • 加强针研究纳入6,156,100人,接种一剂单价加强针。

主要发现

  • BNT162b2基础免疫后AMI的IRR为1.04(95%CI:0.91至1.18),加强针后为1.06(95%CI:1.003至1.12)。
  • mRNA-1273基础免疫后AMI的IRR为1.01(95%CI:0.82至1.26),加强针后为1.05(95%CI:0.998至1.11)。
  • BNT162b2基础免疫后住院PE的IRR为1.19(95%CI:1.03至1.38),加强针后为0.86(95%CI:0.78至0.95)。
  • mRNA-1273基础免疫后住院PE的IRR为1.15(95%CI:0.94至1.41),加强针后为0.87(95%CI:0.79至0.96)。
  • 研究结果不支持COVID-19 mRNA疫苗暴露升高ITP、DIC、Myo/Peri和BP风险。

临床怎么用

  • 原文结论为未发现AMI、ITP、DIC、BP和Myo/Peri风险增加,PE无一致证据,结果支持美国老年人群接种COVID-19 mRNA疫苗的良好安全性特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevation in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluation of potential associations. METHODS: We conducted two self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged ≥ 65 years. Adjusted incidence rate ratio (IRRs) and 95 % confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following monovalent booster doses for AMI, PE, ITP, Bell's Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri). RESULTS: The primary series study included 3,360,981 individuals who received 6,388,542 primary series doses; the booster study included 6,156,100 individuals with one monovalent booster dose. The AMI IRR following BNT162b2 primary series and booster was 1.04 (95 % CI: 0.91 to 1.18) and 1.06 (95 % CI: 1.003 to 1.12), respectively; for mRNA-1273 primary series and booster, 1.01 (95 % CI: 0.82 to 1.26) and 1.05 (95 % CI: 0.998 to 1.11), respectively. The hospital inpatient PE IRR following BNT162b2 primary series and booster was 1.19 (95 % CI: 1.03 to 1.38) and 0.86 (95 % CI: 0.78 to 0.95), respectively; for mRNA-1273 primary series and booster, 1.15 (95 % CI: 0.94 to 1.41) and 0.87 (95 % CI: 0.79 to 0.96), respectively. The studies' results do not support that exposure to COVID-19 mRNA vaccines elevate the risk of ITP, DIC, Myo/Peri, and BP. CONCLUSION: We did not find an increased risk for AMI, ITP, DIC, BP, and Myo/Peri and there was not consistent evidence for PE after exposure to COVID-19 mRNA primary series or monovalent booster vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the U.S. elderly population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shoaibi A, Lloyd PC, Wong HL, et al. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S. Vaccine. 2023. PMID: 37344261. doi:10.1016/j.vaccine.2023.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。